SEARCH

SEARCH BY CITATION

References

  • 1
    Hawkey CJ. Commentary: risk factors for gastrointestinal bleeding in NSAID users. Aliment Pharmacol Ther 2012; 36: 904.
  • 2
    Lanas A, Goldstein JL, Chan FKL, et al. Risk factors associated with a decrease 2 g/dL in haemoglobin and/or 10% haematocrit in osteoarthritis patients taking celecoxib or a nonselective NSAID plus a PPI in a large randomised controlled trial (CONDOR). Aliment Pharmacol Ther 2012; 36: 48592.
  • 3
    Chan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL. Celecoxib versus omeprazole diclofenac in patients with osteoarthritis rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010; 376: 1739.
  • 4
    Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Zlotnick S, Fort JG. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005; 3: 13341.
  • 5
    Goldstein JL, Eisen GM, Lewis B, et al. Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy. Aliment Pharmacol Ther 2007; 25: 121122.
  • 6
    Hunt RH, Bowen B, Mortensen ER, et al. A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects. Am J Med 2000; 109: 2016.